| scholarly article | Q13442814 |
| P50 | author | Véronique L. Roger | Q110955107 |
| P2093 | author name string | K V Ballman | |
| S E Gabriel | |||
| S J Jacobsen | |||
| C S Crowson | |||
| P J Nicola | |||
| H Maradit-Kremers | |||
| P2860 | cites work | Cardiovascular death in rheumatoid arthritis: a population-based study | Q81484761 |
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE> | Q28204197 | ||
| Acute-phase proteins and other systemic responses to inflammation | Q28296941 | ||
| Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation | Q29547453 | ||
| Inflammatory markers and onset of cardiovascular events: results from the Health ABC study | Q34271279 | ||
| Rochester Epidemiology Project: a unique resource for research in the rheumatic diseases | Q34359522 | ||
| History of the Rochester Epidemiology Project | Q34374377 | ||
| Anemia of chronic disease. | Q34401570 | ||
| The Natural History of Congestive Heart Failure: The Framingham Study | Q34701680 | ||
| Inflammatory mediators and the failing heart: past, present, and the foreseeable future | Q35011415 | ||
| Recent developments in the anemia of chronic disease. | Q35193129 | ||
| Evaluative laboratory testing. Assessing tests that assess disease activity | Q40375304 | ||
| The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials | Q40914450 | ||
| Equivalence of the acute phase reactants C-reactive protein, plasma viscosity, and Westergren erythrocyte sedimentation rate when used to calculate American College of Rheumatology 20% improvement criteria or the Disease Activity Score in patients w | Q41701353 | ||
| Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). | Q43586296 | ||
| The erythrocyte sedimentation rate in congestive heart failure | Q44107718 | ||
| Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study | Q44433022 | ||
| Evaluative laboratory testing practices of United States rheumatologists. | Q45950546 | ||
| How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? | Q46732422 | ||
| Guidelines for the management of rheumatoid arthritis: 2002 Update | Q56212157 | ||
| The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors | Q57422768 | ||
| The risk of congestive heart failure in rheumatoid arthritis: A population-based study over 46 years | Q57540261 | ||
| The erythrocyte sedimentation rate. Guidelines for rational use. | Q64984999 | ||
| Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis | Q73601063 | ||
| Hemodilution is common in patients with advanced heart failure | Q78826206 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| rheumatoid arthritis | Q187255 | ||
| P304 | page(s) | 76-80 | |
| P577 | publication date | 2006-07-03 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis | |
| P478 | volume | 66 |
| Q51506928 | A cross-sectional study of diastolic dysfunction in rheumatoid arthritis and its association with disease activity. |
| Q39110166 | An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy |
| Q87035377 | Arterial stiffness is associated with left ventricular dysfunction in patients with rheumatoid arthritis |
| Q33721605 | Autoantibodies and the risk of cardiovascular events |
| Q38568465 | Cardiovascular comorbidity in rheumatic diseases |
| Q26823443 | Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure |
| Q33943374 | Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment |
| Q33806651 | Cardiovascular morbidity and mortality in rheumatoid arthritis |
| Q38126009 | Cardiovascular risk and inflammatory rheumatic diseases |
| Q90419436 | Diastolic dysfunction in rheumatoid arthritis patients with low disease activity |
| Q37883018 | Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. |
| Q35019085 | Heart disease and rheumatoid arthritis: understanding the risks |
| Q39215532 | Magnetic Resonance Imaging-Detected Myocardial Inflammation and Fibrosis in Rheumatoid Arthritis: Associations With Disease Characteristics and N-Terminal Pro-Brain Natriuretic Peptide Levels |
| Q37658795 | N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR) |
| Q38523001 | Platelet and red blood cell interactions and their role in rheumatoid arthritis. |
| Q36951050 | Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors |
| Q94584824 | Prognostic values of the SYNTAX score II and the erythrocyte sedimentation rate on long-term clinical outcomes in STEMI patients with multivessel disease: a retrospective cohort study |
| Q92442225 | Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis |
| Q41264898 | Sudden cardiac death in patients with rheumatoid arthritis |
| Q37894193 | TNF alpha antagonist therapy and safety monitoring |
| Q37027093 | The Rochester Epidemiology Project: exploiting the capabilities for population-based research in rheumatic diseases |
| Q36790405 | The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study |
| Q36596365 | The heart and cardiovascular manifestations in rheumatoid arthritis |
| Q35915244 | The influence of rheumatoid arthritis disease characteristics on heart failure. |
| Q38091933 | The role of B-cells in heart failure |
Search more.